Research funder · United States
Alzheimer's Drug Discovery Foundation
Nonprofit organization
- Grants since 2016
- 326
- Awarded, last 5 years (where amounts are published)
- $245.1M
- Funded works, last 5 years
- 1 178
- Funded works, all time
- 2 272
Grants
2025–2027 · research · Clinical
Phase 3 trial of dopaminergic therapy in patients with Alzheimer’s disease.
Giacomo Koch · Neuroscios Gmbh
2025–2027 · research · Clinical
A Phase 2 Clinical Trial to Study the Effect of TPN-101, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with Alzheimer's Disease
Andrew Satlin · Transposon Therapeutics
2025–2026 · research · Diagnostics Accelerator
Proof-of-Principal clinical study for blood based extracellular vesicle bound biomarker signatures quantifying brain alpha synuclein aggregation state
Richard Batrla · Sunbird Bio
2024–2029 · research · Prevention
Expanding AD Biomarkers in NIA funded PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
Roberta Brinton · University of Arizona
2024–2027 · research · Diagnostics Accelerator
Certified Reference Material and Method for plasma p-tau217
Henrik Zetterberg · University of Gothenburg
2024–2026 · prize · Diagnostics Accelerator
2023 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery: Validation of a Globally Scalable AD Screening Tool: A/T/dN
Rhoda Au · Boston University
2024–2025 · research · Diagnostics Accelerator
ESYA AD360: A BLOOD-BASED DIAGNOSTIC PLATFORM FOR ALZHEIMER’S DISEASE DIAGNOSIS AND DIFFERENTIATE FROM OTHER COGNITIVE IMPAIRMENTS
Souvik Modi · Esya Inc
2024–2026 · research · Drug Discovery
Lead Optimization of SHIP1 Inhibitors and Biomarker Development for the Treatment of Alzheimer's Disease
Timothy Richardson · Indiana University
2024–2025 · research · Diagnostics Accelerator
CEOi Digital Cognitive Assessments Workgroup
Ben Tiede · UsAgainstAlzheimer
2024–2026 · research · Diagnostics Accelerator
Digital Multimodal Neuropsychological Phenotyping for the Detection of Cognitive Decline in Aging Adults
Russell Banks · Neurotrack Technologies (United States)
2024–2026 · research · Biomarkers
Biomarker-driven phenotyping for Alzheimer's disease and related dementia
Simon Mead · University College London
2024–2027 · research · Diagnostics Accelerator
Clinical value evaluation of the awAIr(TM)-CAS test based on hyperspectral retinal imaging
Jean-Philippe Sylvestre · Optina Diagnostics (Canada)
2024–2026 · research · Diagnostics Accelerator
A multi-omics brain aging test for tracking cognitive sharpness and risk of dementia
Christin Glorioso · Neuroage Therapeutics
2024–2029 · research · Biomarkers
Alzheimer's Disease Biomarker Observatory (BMO): Biomarker Data Capture, Curation, and Provision of Access
Jeffrey Cummings · University of Nevada, Las Vegas
2024–2028 · research · Clinical
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 26-Week Study to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Subtype of Frontotemporal Lobar Degeneration (FTLD).
Fred Grossman · Coya Therapeutics
2024–2027 · research · Biomarkers
PET imaging activated astrocytes in Alzheimer's Disease continuum with [18F]F-DED
Andrew Stephens · Life Molecular Imaging, Ltd
2024–2026 · research · Clinical
AD back on track: CMC and preclinical development activities to support Phase 1 regulatory filing of OT-003, a novel small molecule TrkB receptor modulator with disease-modifying potential
Alleyn Plowright · Pangea Botanica Ltd
2024–2027 · research · Drug Discovery
Discovery of TRPM2 Inhibitors for the Treatment of Neuroinflammation
Donald Weaver · Uhn-krembil
2024–2026 · research · Drug Discovery
Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology.
Glenn Larsen · Aquinnah Pharmaceuticals
2024–2026 · research · Drug Discovery
IND-enabling studies for GliaPharm’s lead candidate to rescue hypometabolism in Alzheimer’s disease
Pierre Magistretti · Gliapharm Sa
2024–2025 · research · Drug Discovery
Preclinical study to explore the proof-of concept of trametinib at the lowest dose for the development of a disease-modifying treatment for Alzheimer’s disease
Sungho Han · Genuv Inc.
2024–2025 · prize · Drug Discovery
2024 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery:
Henrik Zetterberg · University of Gothenburg
2024–2025 · research · Diagnostics Accelerator
Blood Based Mitochondrial Biomarkers for Alzheimer's Disease
Heather Wilkins · University of Kansas Medical Center
2024–2029 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
Christopher Rowe · Florey Institute of Neuroscience and Mental Health
2024–2026 · research · Diagnostics Accelerator
Investigating ViewMind ocular digital cognitive biomarkers and their relationship to tau and amyloid PET scans.
Yaakov Stern · Viewmind
2024–2027 · research · Drug Discovery
Development of a novel, highly brain penetrant CSF1R inhibitor for the treatment of FTD, ALS, AD and related dementias.
Ryan Lim · Modulo Bio, Inc.
2024–2027 · research · Drug Discovery
Targeting Caspase-2 to Repair Synaptic Function in Tauopathies
Karen Ashe · University of Minnesota
2024–2025 · research · Drug Discovery
Mitigating TDP-43 loss of function and disease initiation in FTD thru repair of the Nuclear Pore and CHMP7/ESCRT3 dysfunction.
Jeffrey Rothstein · Johns Hopkins University
2024–2025 · research · Clinical
Phase 2b/3 trial of LM11A-31-BHS for Alzheimer's Disease
Anne Longo · Pharmatrophix
2024–2025 · research · Clinical
Strategic Collaborative Framework for developing and testing innovative combination therapies, biomarkers, and digital solutions for precision prevention of cognitive decline and Alzheimer’s Disease and Related Dementias (previously: FINGERS Brain Health Institute - ADDF Memorandum of Understanding Planning Grant)
Miia Kivipelto · Fingers Brain Health Institute
2024–2027 · research · Diagnostics Accelerator
Plasma pTau217 detection with the LUMIPULSE G platform as indicator for Alzheimer’s Disease
Manu Vandijck · Fujirebio Europe Nv
2024–2027 · research · Diagnostics Accelerator
Validation of a Mass Spectrometry-Based Clinical Lab Workstation and Global Scale-up of Precivity(TM) In-Vitro Diagnostic Testing
Joel Braunstein · C2N Diagnostics (United States)
2024–2026 · research · Diagnostics Accelerator
Plasma proteomic approach to identify CSF defined molecular subtypes of Alzheimer’s disease for personalised treatment
Betty Tijms · Stichting Amsterdam Umc
2024–2025 · research · Diagnostics Accelerator
Alzheimer’s Moonshot Program
Elizabeth Dale · Startup Health, Llc
2024–2026 · research · Drug Discovery
Using protein thermal shift and a novel cellular thermal shift assay to uncover and progress small molecule correctors of ApoE4
Rosemary Jackson · University of Dundee
2024–2027 · research · Clinical
A 2-Part, phase 2a, Multi-Center, randomised, double blinded, placebo controlled clinical trial investigating safety and tolerability, PK and exploratory efficacy of the M1 selective rigid, orthosteric M1 agonist NSC001 in patients suffering from mild to moderate Alzheimer’s Disease
Manfred Windisch · Nsc-therapeutics Gmbh
2024–2026 · research · Diagnostics Accelerator
The GLX Signature test for diagnosis and monitoring of Alzheimer’s Disease at the point-of-care.
Brian Della Valle · Glx Analytix Aps
2023–2025 · research · Biomarkers
Diffusion MRI-based white matter measures as monitoring biomarkers for clinical trials in Alzheimer’s disease
Maxime Descoteaux · Imeka
2023–2025 · research · Biomarkers
acTau-174 as a novel biomarker of tau pathology in frontotemporal dementia
Charlotte Teunissen · University of Amsterdam
2023–2027 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
Javier Solana Sanchez · Barcelona Brain Health Initiative